Ying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ying Liu has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Xilin Zhu
Chinese Academy of Medical Sciences and Peking Union Medical College Institute of Basic Medical Sciences
10 shared publicationsXiaopan Wu
State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, School of Basic Medicine, Peking Union Medical College, Beijing 100005, China
7 shared publicationsFenghe Niu
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; School of Basic Medicine, Peking Union Medical College
3 shared publicationsHua Lin
Department of Neurology, Xuanwu Hospital, Capital Medical University, The Beijing Key Laboratory of Neuromodulation, Beijing 100053, China
3 shared publicationsJingyun Li
National Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences; School of Basic Medicine, Peking Union Medical College, Beijing 100005, People's Republic of China.
3 shared publicationsLiping Li
Department of Neurology, Xuanwu Hospital, Capital Medical University, The Beijing Key Laboratory of Neuromodulation, Beijing 100053, China
3 shared publications
Latest Publications
- Open Access
- 21 June 2023
- Published by Springer Nature in Research Square
PPM1H is Down-Regulated by ATF6 and Dephosphorylates p-RPS6KB1 to Inhibit Progression of Hepatocellular Carcinoma
Background: Our previous studies found that polymorphism of activating transcription factor 6 (ATF6) was associated with susceptibility to hepatocellular carcinoma (HCC), and ATF6 promoted HCC progression. So genes down-regulated by ATF6 might play a tumor suppressing role. In present study, we aimed to identify downstream genes down-regulated by ATF6, and clarified its role in HCC progression.Methods: To determine the role of ATF6 on downstream gene expression, qRT-PCR and western blot were performed in HCC cells and liver specifically Atf6-knocked out mice. Tumor tissues from 134 HCC patients were analyzed by immunohistochemistry. Then, MTT, transwell and clone formation assays were performed in hepatoma cells. DEN/CCl4 induced HCC mouse model and nude mice tumorigenicity assay were conducted to investigate the effect of PPM1H on HCC tumorigenesis and development. 3D model of PPM1H was obtained by homology multi-template modeling, the potential substrates of PPM1H were screened by Rosetta and verified through co-immunoprecipitation, western blot and in vitro phosphatase assays.Results: The expression of Protein phosphatase magnesium or manganous dependent 1H (PPM1H) mRNA and protein can be inhibited by ATF6. PPM1H inhibited proliferation, migration, invasion and clone formation of cancer cells. PPM1H inhibited induced HCC nodules formation and tumor xenograft growth in two mouse models. The protein docking energy of RPS6KB1 with PPM1H in the BMP/TGFβ pathway is the lowest, and PPM1H directly dephosphorylated p-RPS6KB1. PPM1H exhibited higher expression level in adjacent para-cancer tissues than in HCC tissues. Patients with higher expression of PPM1H indicated a better prognosis.Conclusions: We first discovered RPS6KB1 as a new PPM1H dephosphorylation substrate. PPM1H exhibited suppressive effect on the progression of HCC through dephosphorylating p-RPS6KB1. This might contribute to finding novel target for therapy of HCC.
- 21 June 2023
- Published by Springer Nature in Research Square
Open AccessPPM1H is Down-Regulated by ATF6 and Dephosphorylates p-RPS6KB1 to Inhibit Progression of Hepatocellular Carcinoma
Background: Our previous studies found that polymorphism of activating transcription factor 6 (ATF6) was associated with susceptibility to hepatocellular carcinoma (HCC), and ATF6 promoted HCC progression. So genes down-regulated by ATF6 might play a tumor suppressing role. In present study, we aimed to identify downstream genes down-regulated by ATF6, and clarified its role in HCC progression.Methods: To determine the role of ATF6 on downstream gene expression, qRT-PCR and western blot were performed in HCC cells and liver specifically Atf6-knocked out mice. Tumor tissues from 134 HCC patients were analyzed by immunohistochemistry. Then, MTT, transwell and clone formation assays were performed in hepatoma cells. DEN/CCl4 induced HCC mouse model and nude mice tumorigenicity assay were conducted to investigate the effect of PPM1H on HCC tumorigenesis and development. 3D model of PPM1H was obtained by homology multi-template modeling, the potential substrates of PPM1H were screened by Rosetta and verified through co-immunoprecipitation, western blot and in vitro phosphatase assays.Results: The expression of Protein phosphatase magnesium or manganous dependent 1H (PPM1H) mRNA and protein can be inhibited by ATF6. PPM1H inhibited proliferation, migration, invasion and clone formation of cancer cells. PPM1H inhibited induced HCC nodules formation and tumor xenograft growth in two mouse models. The protein docking energy of RPS6KB1 with PPM1H in the BMP/TGFβ pathway is the lowest, and PPM1H directly dephosphorylated p-RPS6KB1. PPM1H exhibited higher expression level in adjacent para-cancer tissues than in HCC tissues. Patients with higher expression of PPM1H indicated a better prognosis.Conclusions: We first discovered RPS6KB1 as a new PPM1H dephosphorylation substrate. PPM1H exhibited suppressive effect on the progression of HCC through dephosphorylating p-RPS6KB1. This might contribute to finding novel target for therapy of HCC.
- Open Access
- 1 March 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (3) , 1335-1348
ADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response
- 1 March 2021
- Published by Elsevier in Molecular Therapy
- Vol. 29 (3) , 1335-1348
Open AccessADAR1 Stimulation by IFN-α Downregulates the Expression of MAVS via RNA Editing to Regulate the Anti-HBV Response
- 1 January 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 121, 274-285
PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by influencing synaptic function in the primary motor cortex of rats
- 1 January 2019
- Published by Elsevier in Neurobiology of Disease
- Vol. 121, 274-285
PRRT2 deficiency induces paroxysmal kinesigenic dyskinesia by influencing synaptic function in the primary motor cortex of rats
- 1 October 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 41, 81-85
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy
- 1 October 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 41, 81-85
Identification of a novel mutation in PLA2G6 gene in a Chinese pedigree with familial cortical myoclonic tremor with epilepsy
- 14 November 2015
- Published by Springer Nature in Journal of Genetics
- Vol. 94 (4) , 637-642
Combined effect between two functional polymorphisms of SLC6A12 gene is associated with temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is the most common epilepsy subtype with complex genetic structure. A recent study in four populations (Ireland, UK, Australia and Finland) reported an allelic association between betaine/GABA transporter-1 (BGT-1 or SLC6A12) and mesial temporal lobe epilepsy with hippocampal sclerosis. To demonstrate the association between SLC6A12 gene polymorphisms and TLE, TaqMan method was used to genotype five single-nucleotide polymorphisms of SLC6A12 gene in 358 TLE patients and 596 nonepileptic control subjects of Chinese Han origin. Real-time PCR was used to detect the effects of variations on gene expression associated with TLE. Though, the single-marker analysis did not demonstrate allelic association with TLE, rs542736–rs557881 interaction showed significant association. The SLC6A12 expression levels in peripheral blood mononuclear cells were significantly higher in TLE patients than in control subjects and were correlated to rs542736 G–rs557881 A haplotypes. Our preliminary results suggested combined effect of two common polymorphisms on SLC6A12 gene may be associated with TLE, but the precise mechanism needs further investigation.
- 14 November 2015
- Published by Springer Nature in Journal of Genetics
- Vol. 94 (4) , 637-642
Combined effect between two functional polymorphisms of SLC6A12 gene is associated with temporal lobe epilepsy
Temporal lobe epilepsy (TLE) is the most common epilepsy subtype with complex genetic structure. A recent study in four populations (Ireland, UK, Australia and Finland) reported an allelic association between betaine/GABA transporter-1 (BGT-1 or SLC6A12) and mesial temporal lobe epilepsy with hippocampal sclerosis. To demonstrate the association between SLC6A12 gene polymorphisms and TLE, TaqMan method was used to genotype five single-nucleotide polymorphisms of SLC6A12 gene in 358 TLE patients and 596 nonepileptic control subjects of Chinese Han origin. Real-time PCR was used to detect the effects of variations on gene expression associated with TLE. Though, the single-marker analysis did not demonstrate allelic association with TLE, rs542736–rs557881 interaction showed significant association. The SLC6A12 expression levels in peripheral blood mononuclear cells were significantly higher in TLE patients than in control subjects and were correlated to rs542736 G–rs557881 A haplotypes. Our preliminary results suggested combined effect of two common polymorphisms on SLC6A12 gene may be associated with TLE, but the precise mechanism needs further investigation.
- 2 July 2015
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 126 (5) , 436-441
Role of BDNF Val66Met functional polymorphism in temporal lobe epilepsy
Various studies suggested that brain-derived neurotrophic factor (BDNF) gene polymorphisms contributed to the development of many neurological disorders. However, whether BDNF Val66Met polymorphism is associated with epilepsy remains controversial. In our study, we tried to investigate the effects of this functional polymorphism on the occurrence of temporal lobe epilepsy (TLE) and its clinical phenotypes. Case-control studies were employed to study the association between BDNF Val66Met polymorphism and TLE, as well as its clinical phenotypes, and magnetic resonance imaging examinations and voxel-based morphometry analyses were carried out for further study. Our results showed that the frequency of Met allele was found to be lower in the TLE patients compared with the control subjects (43.9% vs. 48.6%, P = 0.012, OR = 1.21, 95% CI = 1.04–1.41), and the frequency of Met66 allele carriers in the TLE with hippocampal sclerosis was significantly lower than those non-carriers (20.5% vs. 29.1%, P = 0.040). However, we failed to find the difference between different genotypes and hippocampal asymmetry. Our findings suggested that BDNF Val66Met polymorphism might be correlated with epileptogenesis, and Met66 allele might play a protective role against the occurrence of TLE.
- 2 July 2015
- Published by Taylor & Francis in International Journal of Neuroscience
- Vol. 126 (5) , 436-441
Role of BDNF Val66Met functional polymorphism in temporal lobe epilepsy
Various studies suggested that brain-derived neurotrophic factor (BDNF) gene polymorphisms contributed to the development of many neurological disorders. However, whether BDNF Val66Met polymorphism is associated with epilepsy remains controversial. In our study, we tried to investigate the effects of this functional polymorphism on the occurrence of temporal lobe epilepsy (TLE) and its clinical phenotypes. Case-control studies were employed to study the association between BDNF Val66Met polymorphism and TLE, as well as its clinical phenotypes, and magnetic resonance imaging examinations and voxel-based morphometry analyses were carried out for further study. Our results showed that the frequency of Met allele was found to be lower in the TLE patients compared with the control subjects (43.9% vs. 48.6%, P = 0.012, OR = 1.21, 95% CI = 1.04–1.41), and the frequency of Met66 allele carriers in the TLE with hippocampal sclerosis was significantly lower than those non-carriers (20.5% vs. 29.1%, P = 0.040). However, we failed to find the difference between different genotypes and hippocampal asymmetry. Our findings suggested that BDNF Val66Met polymorphism might be correlated with epileptogenesis, and Met66 allele might play a protective role against the occurrence of TLE.
- Open Access
- 23 April 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 9134-9151
PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
Paroxysmal kinesigenic choreoathetosis (PKC) is an inherited disease of the nervous system. We previously identified PRRT2 as the causative gene of PKC. However, as little is known about the function of PRRT2, elucidating its function will benefit not only PKC studies, but also many other related disorders. Here, we reveal higher levels of glutamate in the plasma of PKC patients and the culture medium of neurons following knock-out Prrt2 expression. Using double immunostaining assays we confirm Prrt2 is located at the glutamatergic neurons in accordance with its function. Our co-immunoprecipitation assays reveal mutant PRRT2 interferes with SNAP25 and GRIA1 interactions, respectively. Furthermore, using live-labeling techniques, we confirmed co-transfection with mutant PRRT2 caused an increase in GRIA1 distribution on the cell surface. Therefore, our results suggest that mutant PRRT2, probably through its weakened interaction with SNAP25, affects glutamate signaling and glutamate receptor activity, resulting in the increase of glutamate release and subsequent neuronal hyperexcitability.
- 23 April 2015
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 16 (5) , 9134-9151
Open AccessPRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
Paroxysmal kinesigenic choreoathetosis (PKC) is an inherited disease of the nervous system. We previously identified PRRT2 as the causative gene of PKC. However, as little is known about the function of PRRT2, elucidating its function will benefit not only PKC studies, but also many other related disorders. Here, we reveal higher levels of glutamate in the plasma of PKC patients and the culture medium of neurons following knock-out Prrt2 expression. Using double immunostaining assays we confirm Prrt2 is located at the glutamatergic neurons in accordance with its function. Our co-immunoprecipitation assays reveal mutant PRRT2 interferes with SNAP25 and GRIA1 interactions, respectively. Furthermore, using live-labeling techniques, we confirmed co-transfection with mutant PRRT2 caused an increase in GRIA1 distribution on the cell surface. Therefore, our results suggest that mutant PRRT2, probably through its weakened interaction with SNAP25, affects glutamate signaling and glutamate receptor activity, resulting in the increase of glutamate release and subsequent neuronal hyperexcitability.
- 24 March 2014
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (7) , 1105-1112
BTNL2 associated with the immune response to hepatitis B vaccination in a Chinese Han population
No response to hepatitis B vaccination is a complex phenomenon, which is induced by the combinations of environmental and genetic factors. The aim of the study was to investigate the association between the polymorphisms of the butyrophilin‐like 2 (BTNL2) gene and the immune response to hepatitis B vaccination in a Chinese Han population. A total of 7 single nucleotide polymorphisms in the BTNL2 gene were analyzed in 566 non‐responders and 1,040 high‐responders to hepatitis B vaccination. The alleles T, T, C, A, G of rs3763316, rs3763311, rs9268494, rs3806156, and rs2076530 were associated with no response to hepatitis B vaccination (P = 0.015, odds ratio (OR) = 1.20; P = 0.029, OR = 1.18; P = 2.00E−07, OR = 1.58; P = 0.002, OR = 1.27; P = 2.90E−06, OR = 1.41, respectively). Whereas, the alleles T, C of rs9268501 and rs3763313 played significantly protective roles in the immune response to hepatitis B vaccination (P = 0.007, OR = 0.81; P = 0.004, OR = 0.74). Besides, the risks of no response to hepatitis B vaccination were increased significantly among individuals harbored the haplotypes of G‐T‐A‐T‐C‐A‐G (P = 0.038, OR = 1.48), G‐T‐A‐T‐C (P < 0.0001, OR = 2.34), A‐A (P < 0.0001, OR = 4.08), and C‐G (P < 0.0001, OR = 4.75). However, the haplotype of G‐C‐A‐T‐C (P = 1.00E−04, OR = 0.54) exhibited a protective role in the immune response to hepatitis B vaccination in the study. These findings suggest that polymorphisms in the BTNL2 gene might play a vital role in determining the outcome of the immune response to hepatitis B vaccination. J. Med. Virol. 86:1105–1112, 2014.
- 24 March 2014
- Published by Wiley in Journal of Medical Virology
- Vol. 86 (7) , 1105-1112
BTNL2 associated with the immune response to hepatitis B vaccination in a Chinese Han population
No response to hepatitis B vaccination is a complex phenomenon, which is induced by the combinations of environmental and genetic factors. The aim of the study was to investigate the association between the polymorphisms of the butyrophilin‐like 2 (BTNL2) gene and the immune response to hepatitis B vaccination in a Chinese Han population. A total of 7 single nucleotide polymorphisms in the BTNL2 gene were analyzed in 566 non‐responders and 1,040 high‐responders to hepatitis B vaccination. The alleles T, T, C, A, G of rs3763316, rs3763311, rs9268494, rs3806156, and rs2076530 were associated with no response to hepatitis B vaccination (P = 0.015, odds ratio (OR) = 1.20; P = 0.029, OR = 1.18; P = 2.00E−07, OR = 1.58; P = 0.002, OR = 1.27; P = 2.90E−06, OR = 1.41, respectively). Whereas, the alleles T, C of rs9268501 and rs3763313 played significantly protective roles in the immune response to hepatitis B vaccination (P = 0.007, OR = 0.81; P = 0.004, OR = 0.74). Besides, the risks of no response to hepatitis B vaccination were increased significantly among individuals harbored the haplotypes of G‐T‐A‐T‐C‐A‐G (P = 0.038, OR = 1.48), G‐T‐A‐T‐C (P < 0.0001, OR = 2.34), A‐A (P < 0.0001, OR = 4.08), and C‐G (P < 0.0001, OR = 4.75). However, the haplotype of G‐C‐A‐T‐C (P = 1.00E−04, OR = 0.54) exhibited a protective role in the immune response to hepatitis B vaccination in the study. These findings suggest that polymorphisms in the BTNL2 gene might play a vital role in determining the outcome of the immune response to hepatitis B vaccination. J. Med. Virol. 86:1105–1112, 2014.
- Open Access
- 26 November 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (8) , 2210-2219
A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations
Vaccination against hepatitis B virus is an effective and routine practice that can prevent infection. However, 5–10% of healthy adults fail to produce protective levels of antibody against the hepatitis B vaccination. It has been reported that host genetic variants might affect the immune response to hepatitis B vaccination. Here, we reported a genome-wide association study in a Chinese Han population consisting of 108 primary high-responders and 77 booster non-responders to hepatitis B vaccination using the Illumina HumanOmniExpress Beadchip. We identified 21 SNPs at 6p21.32 were significantly associated with non-response to booster hepatitis B vaccination (P-value −6). The most significant SNP in the region was rs477515, located ∼12 kb upstream of the HLA-DRB1 gene. Its P-value (4.81 × 10−8) exceeded the Bonferroni-corrected genome-wide significance threshold. Four tagging SNPs (rs477515, rs28366298, rs3763316 and rs13204672) that capture genetic information of these 21 SNPs were validated in three additional Chinese Han populations, consisting of 1336 primary high-responders and 420 primary non-responders. The four SNPs continued to show significant associations with non-response to hepatitis B vaccination (P-combined = 3.98 × 10−13– 1.42 × 10−8). Further analysis showed that the rs477515 was independently associated with non-response to hepatitis B vaccination with correction for other three SNPs in our GWAS and the known hepatitis B vaccine immunity associated SNP in previous GWAS. Our findings suggest that the rs477515 was an independent marker associated with non-response to hepatitis B vaccination and HLA-DR region might be a critical susceptibility locus of hepatitis B vaccine-induced immunity.
- 26 November 2013
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 23 (8) , 2210-2219
Open AccessA genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations
Vaccination against hepatitis B virus is an effective and routine practice that can prevent infection. However, 5–10% of healthy adults fail to produce protective levels of antibody against the hepatitis B vaccination. It has been reported that host genetic variants might affect the immune response to hepatitis B vaccination. Here, we reported a genome-wide association study in a Chinese Han population consisting of 108 primary high-responders and 77 booster non-responders to hepatitis B vaccination using the Illumina HumanOmniExpress Beadchip. We identified 21 SNPs at 6p21.32 were significantly associated with non-response to booster hepatitis B vaccination (P-value −6). The most significant SNP in the region was rs477515, located ∼12 kb upstream of the HLA-DRB1 gene. Its P-value (4.81 × 10−8) exceeded the Bonferroni-corrected genome-wide significance threshold. Four tagging SNPs (rs477515, rs28366298, rs3763316 and rs13204672) that capture genetic information of these 21 SNPs were validated in three additional Chinese Han populations, consisting of 1336 primary high-responders and 420 primary non-responders. The four SNPs continued to show significant associations with non-response to hepatitis B vaccination (P-combined = 3.98 × 10−13– 1.42 × 10−8). Further analysis showed that the rs477515 was independently associated with non-response to hepatitis B vaccination with correction for other three SNPs in our GWAS and the known hepatitis B vaccine immunity associated SNP in previous GWAS. Our findings suggest that the rs477515 was an independent marker associated with non-response to hepatitis B vaccination and HLA-DR region might be a critical susceptibility locus of hepatitis B vaccine-induced immunity.
- Open Access
- 28 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77315
Replication of Genome Wide Association Studies on Hepatocellular Carcinoma Susceptibility Loci in a Chinese Population
Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population. In the present study, we sought to determine whether these SNPs are predictive for HBV-related HCC development in other Chinese population as well. We genotyped 4 SNPs, rs2596542, rs9275572, rs17401966, rs7574865, in 506 HBV-related HCC patients and 772 chronic hepatitis B (CHB) patients in Han Chinese by TaqMan methods. Odds ratio(OR)and 95% confidence interval (CI) were calculated by logistic regression. In our case-control study, significant association between rs9275572 and HCC were observed (P = 0.02, OR = 0.73, 95% CI = 0.56–0.95). In the further haplotype analysis between rs2596542 at 6p21.33 and rs9275572 at 6p21.3, G-A showed a protective effect on HBV-related HCC occurrence (P<0.001, OR = 0.66, 95% CI = 0.52–0.84). These findings provided convincing evidence that rs9275572 significantly associated with HBV-related HCC.
- 28 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77315
Open AccessReplication of Genome Wide Association Studies on Hepatocellular Carcinoma Susceptibility Loci in a Chinese Population
Genome-wide association studies (GWAS) have identified three loci (rs17401966 in KIF1B, rs7574865 in STAT4, rs9275319 in HLA-DQ) as being associated with hepatitis B virus-related hepatocellular carcinoma (HBV-related HCC) in a Chinese population, two loci (rs2596542 in MICA, rs9275572 located between HLA-DQA and HLA-DQB) with hepatitis C virus-related HCC (HCV-related HCC) in a Japanese population. In the present study, we sought to determine whether these SNPs are predictive for HBV-related HCC development in other Chinese population as well. We genotyped 4 SNPs, rs2596542, rs9275572, rs17401966, rs7574865, in 506 HBV-related HCC patients and 772 chronic hepatitis B (CHB) patients in Han Chinese by TaqMan methods. Odds ratio(OR)and 95% confidence interval (CI) were calculated by logistic regression. In our case-control study, significant association between rs9275572 and HCC were observed (P = 0.02, OR = 0.73, 95% CI = 0.56–0.95). In the further haplotype analysis between rs2596542 at 6p21.33 and rs9275572 at 6p21.3, G-A showed a protective effect on HBV-related HCC occurrence (P<0.001, OR = 0.66, 95% CI = 0.52–0.84). These findings provided convincing evidence that rs9275572 significantly associated with HBV-related HCC.